CareDx, Inc
Hot onWhy it's trendingX mentions rising faster than the marketMoving on elevated volumeBacked by solid revenue growth$39.62-1.8%YTD+114.1%1Y+110.1%
Mentions · last 7 days
82
Price updated 13m ago·X counts updated 20h ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $CDNA, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $CDNA.
Medical - Diagnostics & Research
No material change from last week — pharma R&D spending is recovering and CDMO demand is growing as drug pipelines advance toward clinical trials.
Industry benchmark
13-name peer basket
+27.4%YTD
+55.5%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-255.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-3.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-3.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
3.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
5.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-2.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
68.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q1 2026Apr 28, 2026$0.34$0.11+209.1%
Q4 2025Feb 24, 2026$0.12$0.02+503.0%
Q3 2025Nov 4, 2025$0.28$0.13+115.4%
Q2 2025Aug 6, 2025$0.10$0.12-16.7%
Next earningsWed, Aug 5·consensus EPS $0.22
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$117.7M+39.0%71.4%1.5%$0.05$514K
Q4 FY25$108.4M+25.2%66.6%-5.4%$-0.08$19.7M
Q3 FY25$100.1M+20.7%68.7%2.0%$0.03$36.1M
Q2 FY25$86.7M-6.1%66.9%-12.8%$-0.16$8.9M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$455.9M$455.5M – $456.3M$0.93$0.90 – $0.965
FY27$481.3M$481.0M – $481.5M$1.13$1.09 – $1.165
FY28$507.2M$493.0M – $516.0M$1.53$1.47 – $1.562
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.4.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.100%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+64.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+105.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatLow float · 49.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today9.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.435-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KAcquisition completedJul 78-K — Item 2.01: Acquisition completed · Item 7.01: Press release / Reg FD
AI summary
8-KOfficer or director changeJun 158-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary
8-KMaterial agreementApr 288-K — Item 1.01: Material agreement · Item 2.02: Earnings release · Item 7.01: Press release / Reg FD · Item 8.01: Other event
8-K/AOfficer or director change (amended)Apr 238-K/A — Item 5.02: Officer or director change
8-KMaterial agreementApr 168-K — Item 1.01: Material agreement · Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
8-K/AOfficer or director change (amended)Feb 258-K/A — Item 2.02: Earnings release · Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
+ 10 other (3 proxys · 3 13Gs · 1 10-Q · 1 ARS) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage DeterminationCareDx Completes Naveris Acquisition and Expands Oncology ReachCareDx: The Transplant Platform Is Becoming A Specialty Diagnostics CompounderCareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
In themes
Explore the broader themes this ticker is being talked about under.
More in Medical - Diagnostics & Research
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $CDNA on X in the last 7 days.